As the latest earnings results from pharma giant Eli Lilly and Co. (NYSE: LLY) confirm, GLP-1 agonists are still a very big business. Despite changes to Medicare and a reimbursement program in China that could threaten to drag down prices and cut into margins, massive volume growth for some of the leading GLP-1 products has helped companies like Eli Lilly improve revenue by a whopping 39% year over year (YOY) in Q3 2026. The demand remains massive.
Investors looking to get in on this opportunity have multiple options: in addition to the drugmakers themselves, there are now dedicated exchange-traded funds (ETFs) providing broader industry access. These include the Roundhill GLP-1 & Weight Loss ETF (NASDAQ: OZEM), which has a particular focus on GLP-1s. Recently, though, an alternative fund utilizing a similar strategy launched: the REX Peptide ETF (NASDAQ: PEPT), which began trading in October 2026. Though it remains much smaller than its established peer OZEM, it offers a distinct approach that is not entirely interchangeable.